Shawn Johnson East started stressing as soon as she found out when her third child was due: smack-dab in the middle of ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

As of last year, RSV vaccination with Abrysvo has been recommended for pregnant women in the United States from 32 to 36 ...

The good news: In October, a new preventive medicine, the monoclonal antibody Nirsevimab, became available to babies and at-risk toddlers to help protect them from RSV (Respiratory Syncytial Virus).

Last year, a prenatal maternal vaccine (Avrexy) and a long-lasting monoclonal antibody called nirsevimab were approved for ...

The following is a summary of "Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children," published in the September 2024 issue of Pediatrics by Domachowske et al. Children who are ...

The following is a summary of "Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments," published in the September 2024 issue of Pediatrics by Martínez et al. In the 2023–2024 ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Overall, 44.6 percent of 866 women with an infant born during August 2023 to March 2024 reported infant receipt of nirsevimab ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Provider recommendation for maternal vaccination or infant nirsevimab linked to higher immunization coverage. HealthDay News — In the 2023 to 2024 respiratory syncytial virus (RSV) season ...